Frequent MED12 mutations in phyllodes tumours of the breast

British Journal of Cancer

Volumn 112, Issue 10, 2015, Pages 1703-1708

  Yoshida, M ^a   Sekine, S ^a,b   Ogawa, R ^b   Yoshida, H ^a   Maeshima, A ^b   Kanai, Y ^b   Kinoshita, T ^a   Ochiai, A ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

breast; fibroadenoma; MED12; phyllodes tumour

Indexed keywords

PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; MED12 PROTEIN, HUMAN; MEDIATOR COMPLEX;

ARTICLE; BREAST FIBROADENOMA; CYSTOSARCOMA PHYLLOIDES; EXON; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MED12 GENE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; TUMOR GENE; ADOLESCENT; ADULT; AGED; BREAST TUMOR; FEMALE; FIBROADENOMA; GENETICS; MIDDLE AGED; MUTATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; FEMALE; FIBROADENOMA; HUMANS; MEDIATOR COMPLEX; MIDDLE AGED; MUTATION; PHYLLODES TUMOR; YOUNG ADULT;

EID: 84929271920     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.116     Document Type: Article

References (38)

1. Abe M, Miyata S, Nishimura S, Iijima K, Makita M, Akiyama F, Iwase T. (2011). Malignant transformation of breast fibroadenoma to malignant phyllodes tumor: long-Term outcome of 36 malignant phyllodes tumors. Breast Cancer 18(4): 268-272
2. Bartow SA, Pathak DR, Black WC, Key CR, Teaf SR. (1987). Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study. Cancer 60(11): 2751-2760
3. Bhathal PS, Brown RW, Lesueur GC, Russell IS. (1985). Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer 51(2): 271-278
4. Cani AK, Hovelson DH, McDaniel AS, Sadis S, Haller MJ, Yadati V, Amin AM, Bratley J, Bandla S, Williams PD, Rhodes K, Liu CJ, Quist MJ, Rhodes DR, Grasso CS, Kleer CG, Tomlins SA. (2015). Next-Gen sequencing exposes frequent MED12 mutations and actionable therapeutic targets in phyllodes tumors. Mol Cancer Res; e-pub ahead of print 15 January 2015
5. Cant PJ, Madden MV, Coleman MG, Dent DM. (1995). Non-operative manag ement of breast masses diagnosed as fibroadenoma. Br J Surg 82(6): 792-794
6. Chaney AW, Pollack A, McNeese MD, Zagars GK, Pisters PW, Pollock RE, Hunt KK. (2000). Primary treatment of cystosarcoma phyllodes of the breast. Cancer 89(7): 1502-1511
7. Chen WH, Cheng SP, Tzen CY, Yang TL, Jeng KS, Liu CL, Liu TP. (2005). Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. J Surg Oncol 91(3): 185-194
8. Cimino-Mathews A, Hicks JL, Sharma R, Vang R, Illei PB, De Marzo A, Emens LA, Argani P. (2013). A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway. Hum Pathol 44(11): 2494-2500
9. Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer Jr. WD, Rados MS, Schuyler PA. (1994). Long-Term risk of breast cancer in women with fibroadenoma. N Engl J Med 331(1): 10-15
10. Frantz VK, Pickren JW, Melcher GW, Auchincloss Jr. H. (1951). Indicence of chronic cystic disease in so-called 'normal breasts; a study based on 225 postmortem examinations. Cancer 4(4): 762-783
11. Giri D. (2009). Recurrent challenges in the evaluation of fibroepithelial lesions. Arch Pathol Lab Med 133(5): 713-721
12. Hodges KB, Abdul-Karim FW, Wang M, Lopez-Beltran A, Montironi R, Easley S, Zhang S, Wang N, MacLennan GT, Cheng L. (2009). Evidence for transformation of fibroadenoma of the breast to malignant phyllodes tumor. Appl Immunohistochem Mol Morphol 17(4): 345-350
13. Jones AM, Mitter R, Springall R, Graham T, Winter E, Gillett C, Hanby AM, Tomlinson IP, Sawyer EJ. Phyllodes Tumour Consortium. (2008). A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-Tumoral genetic heterogeneity and new genetic changes on recurrence. J Pathol 214(5): 533-544
14. Kampjarvi K, Park MJ, Mehine M, Kim NH, Clark AD, Butzow R, Bohling T, Bohm J, Mecklin JP, Jarvinen H, Tomlinson IP, van der Spuy ZM, Sjoberg J, Boyer TG, Vahteristo P. (2014). Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas. Hum Mutat 35(9): 1136-1141
15. Kersting C, Kuijper A, Schmidt H, Packeisen J, Liedtke C, Tidow N, Gustmann C, Hinrichs B, Wulfing P, Tio J, Boecker W, van Diest P, Brandt B, Buerger H. (2006). Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab Invest 86(1): 54-61
16. Kuijper A, Buerger H, Simon R, Schaefer KL, Croonen A, Boecker W, van der Wall E, van Diest PJ. (2002). Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. J Pathol 197(5): 575-581
17. Lae M, Vincent-Salomon A, Savignoni A, Huon I, Freneaux P, Sigal-Zafrani B, Aurias A, Sastre-Garau X, Couturier J. (2007). Phyllodes tumors of the breast segregate in two groups according to genetic criteria. Mod Pathol 20(4): 435-444
18. Lawton TJ, Acs G, Argani P, Farshid G, Gilcrease M, Goldstein N, Koerner F, Rowe JJ, Sanders M, Shah SS, Reynolds C. (2014). Interobserver variability by pathologists in the distinction between cellular fibroadenomas and phyllodes tumors. Int J Surg Pathol 22: 695-698
19. Lee AH, Hodi Z, Ellis IO, Elston CW. (2007). Histological features useful in the distinction of phyllodes tumour and fibroadenoma on needle core biopsy of the breast. Histopathology 51(3): 336-344
20. Lim WK, Ong CK, Tan J, Thike AA, Ng CC, Rajasegaran V, Myint SS, Nagarajan S, Nasir ND, McPherson JR, Cutcutache I, Poore G, Tay ST, Ooi WS, Tan VK, Hartman M, Ong KW, Tan BK, Rozen SG, Tan PH, Tan P, Teh BT. (2014). Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat Genet 46(8): 877-880
21. Lindquist KD, van Heerden JA, Weiland LH, Martin Jr. JK. (1982). Recurrent and metastatic cystosarcoma phyllodes. Am J Surg 144(3): 341-343
22. Makinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, Gentile M, Yan J, Enge M, Taipale M, Aavikko M, Katainen R, Virolainen E, Bohling T, Koski TA, Launonen V, Sjoberg J, Taipale J, Vahteristo P, Aaltonen LA. (2011). MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334(6053): 252-255
23. Matsubara A, Sekine S, Yoshida M, Yoshida A, Taniguchi H, Kushima R, Tsuda H, Kanai Y. (2013). Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours. Histopathology 62(4): 657-661
24. McGuire MM, Yatsenko A, Hoffner L, Jones M, Surti U, Rajkovic A. (2012). Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS One 7(3): e33251
25. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. (1987). Breast cancer and atypia among young and middle-Aged women: a study of 110 medicolegal autopsies. Br J Cancer 56(6): 814-819
26. Noguchi S, Yokouchi H, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. (1995). Progression of fibroadenoma to phyllodes tumor demonstrated by clonal analysis. Cancer 76(10): 1779-1785
27. Reinfuss M, Mitus J, Duda K, Stelmach A, Rys J, Smolak K. (1996). The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer 77(5): 910-916
28. Sawhney N, Garrahan N, Douglas-Jones AG, Williams ED. (1992). Epithelial-stromal interactions in tumors. A morphologic study of fibroepithelial tumors of the breast. Cancer 70(8): 2115-2120
29. Sawyer EJ, Hanby AM, Ellis P, Lakhani SR, Ellis IO, Boyle S, Tomlinson IP. (2000). Molecular analysis of phyllodes tumors reveals distinct changes in the epithelial and stromal components. Am J Pathol 156(3): 1093-1098
30. Sawyer EJ, Hanby AM, Rowan AJ, Gillett CE, Thomas RE, Poulsom R, Lakhani SR, Ellis IO, Ellis P, Tomlinson IP. (2002). The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. J Pathol 196(4): 437-444
31. Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, Mosier S, Gocke CD, Epstein JI, Netto GJ, Liu W, Isaacs WB, De Marzo AM, Lotan TL. (2014). Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res 20(4): 890-903
32. Tan PH, Jayabaskar T, Yip G, Tan Y, HilmyM, Selvarajan S, Bay BH. (2005). p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol 18(12): 1527-1534
33. Tan PH, Tse G, Lee A, Simpson JF, Hanby AM. (2012). Fibroepithelial tumours. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (eds) WHO Classification of Tumours of the Breast. pp 142-147. IARC Press: Lyon
34. Tavassoli FA, Eusebi V. (2009). Biphasic tumors. In: Tavassoli FA, Eusebi V (eds) vol. 10AFIP Atlas of Tumor Pathology. pp 315-340. American Registry of Pathology: Washington, DC
35. Tse GM, Putti TC, Kung FY, Scolyer RA, Law BK, Lau TS, Lee CS. (2002). Increased p53 protein expression in malignant mammary phyllodes tumors. Mod Pathol 15(7): 734-740
36. Turunen M, Spaeth JM, Keskitalo S, Park MJ, Kivioja T, Clark AD, Makinen N, Gao F, Palin K, Nurkkala H, Vaharautio A, Aavikko M, Kampjarvi K, Vahteristo P, Kim CA, Aaltonen LA, Varjosalo M, Taipale J, Boyer TG. (2014). Uterine leiomyoma-linked MED12 mutations disrupt mediatorassociated CDK activity. Cell Rep 7(3): 654-660
37. Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, de Wilde RF, Maitra A, Hicks J, Demarzo AM, Shi C, Sharma R, Laheru D, Edil BH, Wolfgang CL, Schulick RD, Hruban RH, Tang LH, Klimstra DS, Iacobuzio-Donahue CA. (2012). Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from welldifferentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 36(2): 173-184
38. Yang X, Kandil D, Cosar EF, Khan A. (2014). Fibroepithelial tumors of the breast: pathologic and immunohistochemical features and molecular mechanisms. Arch Pathol Lab Med 138(1): 25-36